



HUTCHISON CHINA MEDITECH LIMITED

## **Shareholders' Circular and Notice of Extraordinary General Meeting**

**London: Friday, 16 October 2015:** Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the United States Securities and Exchange Commission for a potential offering of American depository shares on the Nasdaq Stock Market ("Offering"), an explanatory circular and a form of proxy have been posted to shareholders. The circular incorporates a letter from the Chairman and a Notice of Extraordinary General Meeting convening an Extraordinary General Meeting to be held at 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN on Tuesday, 10 November 2015 at 10:00 a.m. in order for shareholders to vote upon the resolutions required to enable the directors of Chi-Med to issue new ordinary shares in connection with the potential Offering.

The circular, which has today been posted to shareholders, is also available on the website of Chi-Med at [www.chi-med.com](http://www.chi-med.com).

**Shareholders and potential investors should note that the potential Offering may or may not proceed, and accordingly are advised to exercise caution when dealing in the securities of Chi-Med.**

**Ends**

### **Enquiries:**

**Chi-Med**  
Christian Hogg, CEO

Telephone: +852 2121 8200

**Panmure Gordon (UK) Limited**  
Richard Gray  
Andrew Potts

Telephone: +44 20 7886 2500

**Citigate Dewe Rogerson**  
Anthony Carlisle  
David Dible

Telephone: +44 20 7638 9571  
Mobile: +44 7973 611 888  
Mobile: +44 7967 566 919

### **About Chi-Med**

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).

### **Important information**

This announcement does not constitute a Form F-1 Registration Statement and does not constitute or form, and will not form, part of any offer or invitation to sell or issue, or the solicitation of an offer to purchase or acquire, any of the ordinary shares or American depositary shares or any other securities in the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). Any public offering of securities to be made in the United States will be made by means of a Form F-1 Registration Statement. Such Form F-1 Registration Statement will contain detailed information about the issuer and its management and financial statements. This announcement is being issued pursuant to and in accordance with Rule 135e under the U.S. Securities Act.

### **Forward-Looking Statements**

This announcement may contain forward-looking statements that reflect Chi-Med's current expectations regarding future events, including its intention to complete the potential Offering. Forward looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the possibility that the potential Offering will not be completed within a particular time frame or at a particular amount, or at all, including as a result of regulatory, market or other factors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.